The four startups will have access to capital, business coaching, office space, and Illumina sequencing expertise over a six-month period.
GenEdit, Inc., a biotechnology company with a mission to develop curative therapies through targeted in vivo delivery of genetic medicines, today announced that it has closed a $26 million Series A financing.
